Funding provides for the acceleration of its internal growth strategy and the continued development of Reshape's weight-loss portfolio SAN CLEMENTE, CA / ACCESSWIRE / June 30, 2021 / ReShape ...

SAN CLEMENTE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the ...

ReShape Lifesciences gains approval for its patent application called, "Intragastric Device (For Treating Obesity)." ReShape is trending across different social media platforms as its stock trades on ...

ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...

Before making a voting decision, ReShape’s stockholders are urged to read the joint proxy statement/prospectus and any other documents filed by ReShape with the SEC in connection with the proposed ...

On July 8, 2024, ReShape Lifesciences Inc. entered into a definitive merger agreement with Vyome, under which ReShape and Vyome will combine in an all-stock transaction. At the closing of the merger, ...

IRVINE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host a ...

ReShape Lifesciences announces public offering of 1,054,604 shares at $2.50 each, aiming for $2.6 million in proceeds. ReShape Lifesciences announced the pricing of a public offering of 1,054,604 ...

IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced strategic ...

LONDON, England—Anyone hoping that a third “tiebreaker” trial of the MitraClip against optimal medical therapy (OMT) would help clarify the role of transcatheter edge-to-edge repair (TEER) in heart ...